The pathophysiological process of Alzheimer’s disease (AD) is thought to begin many years
before the diagnosis of AD dementia. This long “preclinical” phase of AD would provide a …

Alzheimer's disease affects millions of people around the world. Currently, there are no
treatments that prevent or slow the disease. Like other neurodegenerative diseases, Alzheimer's …

Neurofilament light chain (NfL) is a promising fluid biomarker of disease progression for
various cerebral proteopathies. Here we leverage the unique characteristics of the Dominantly …

Objectives Amyloid‐β 42 (Aβ 42 ) appears central to Alzheimer's disease (AD) pathogenesis
and is a major component of amyloid plaques. Mean cerebrospinal fluid (CSF) Aβ 42 is …

Vascular contributions to cognitive impairment are increasingly recognized 1 , 2 , 3 , 4 – 5 as
shown by neuropathological 6 , 7 , neuroimaging 4 , 8 , 9 , 10 – 11 , and cerebrospinal fluid …

Background The order and magnitude of pathologic processes in Alzheimer's disease are
not well understood, partly because the disease develops over many years. Autosomal …

Vascular contributions to dementia and Alzheimer’s disease are increasingly recognized 1 ,
2 , 3 , 4 , 5 – 6 . Recent studies have suggested that breakdown of the blood–brain barrier (…

Importance Cerebral amyloid-β aggregation is an early pathological event in Alzheimer
disease (AD), starting decades before dementia onset. Estimates of the prevalence of amyloid …

Objectives To investigate the ability of cerebrospinal fluid (CSF) and plasma measures to
discriminate early-stage Alzheimer disease (AD) (defined by clinical criteria and presence/…

The apolipoprotein E (APOE) ε4 allele is the strongest genetic risk factor for late-onset,
sporadic Alzheimer’s disease (AD). The APOE ε4 allele markedly increases AD risk and …